The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D28K immunohistochemistry
Identifieur interne : 001B66 ( PascalFrancis/Curation ); précédent : 001B65; suivant : 001B67The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D28K immunohistochemistry
Auteurs : P. Damier [France, États-Unis] ; E. C. Hirsch [France] ; Y. Agid [France] ; A. M. Graybiel [États-Unis]Source :
- Brain [ 0006-8950 ] ; 1999.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Cartographie, Homme.
English descriptors
- KwdEn :
Abstract
Parkinson's disease is characterized by massive degeneration of dopamine-containing neurons in the midbrain. However, the vulnerability of these neurons is heterogeneous both across different midbrain dopamine-containing cell groups and within the substantia nigra, the brain structure most affected in this disease. To determine the exact pattern of cell loss and to map the cellular distribution of candidate pathogenic molecules, it is necessary to have landmarks independent of the degenerative process by which to subdivide the substantia nigra. We have developed a protocol for this purpose based on immunostaining for calbindin D28K, a protein present in striatonigral afferent fibres. We used it to examine post-mortem brain samples from seven subjects who had had no history of neurological or psychiatric disease. We found intense immunostaining for calbindin D28K associated with the neuropil of the ventral midbrain. Within the calbindin-positive region, there were conspicuous calbindin-poor zones. Analysed in serial sections, many of the calbindin-poor zones seen in individual sections were continuous with one another, forming elements of larger, branched three-dimensional structures. Sixty per cent of all dopamine-containing neurons in the substantia nigra pars compacta were located within the calbindin-rich zone, which we named the nigral matrix, and 40% were packed together within the calbindin-poor zones, which we named nigrosomes. We identified five different nigrosomes. This organization was consistent from one control brain to another. We propose that subdivision of the human substantia nigra based on patterns of calbindin immunostaining provides a key tool for analysing the organization of the substantia nigra and offers a new approach to analysing molecular expression patterns in the substantia nigra and the specific patterns of nigral cell degeneration in Parkinson's disease.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001479
Links to Exploration step
Pascal:99-0413078Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D<sub>28K</sub> immunohistochemistry</title><author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P." last="Damier">P. Damier</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U289, Hôpital de la Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>France</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology</s1><s2>Cambridge, Massachusetts</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E. C." last="Hirsch">E. C. Hirsch</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U289, Hôpital de la Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U289, Hôpital de la Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Graybiel, A M" sort="Graybiel, A M" uniqKey="Graybiel A" first="A. M." last="Graybiel">A. M. Graybiel</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology</s1><s2>Cambridge, Massachusetts</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">99-0413078</idno><date when="1999">1999</date><idno type="stanalyst">PASCAL 99-0413078 INIST</idno><idno type="RBID">Pascal:99-0413078</idno><idno type="wicri:Area/PascalFrancis/Corpus">001479</idno><idno type="wicri:Area/PascalFrancis/Curation">001B66</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D<sub>28K</sub> immunohistochemistry</title><author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P." last="Damier">P. Damier</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U289, Hôpital de la Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>France</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology</s1><s2>Cambridge, Massachusetts</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E. C." last="Hirsch">E. C. Hirsch</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U289, Hôpital de la Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U289, Hôpital de la Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Graybiel, A M" sort="Graybiel, A M" uniqKey="Graybiel A" first="A. M." last="Graybiel">A. M. Graybiel</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology</s1><s2>Cambridge, Massachusetts</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author></analytic><series><title level="j" type="main">Brain</title><title level="j" type="abbreviated">Brain</title><idno type="ISSN">0006-8950</idno><imprint><date when="1999">1999</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Brain</title><title level="j" type="abbreviated">Brain</title><idno type="ISSN">0006-8950</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Calbindin</term><term>Cartography</term><term>Dopamine</term><term>Dopaminergic neuron</term><term>Exploration</term><term>Human</term><term>Immunohistochemistry</term><term>Locus niger</term><term>Method</term><term>Reproducibility</term><term>Validity</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Locus niger</term><term>Immunohistochimie</term><term>Cholécalcine</term><term>Neurone dopaminergique</term><term>Dopamine</term><term>Cartographie</term><term>Reproductibilité</term><term>Exploration</term><term>Méthode</term><term>Validité</term><term>Homme</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Cartographie</term><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease is characterized by massive degeneration of dopamine-containing neurons in the midbrain. However, the vulnerability of these neurons is heterogeneous both across different midbrain dopamine-containing cell groups and within the substantia nigra, the brain structure most affected in this disease. To determine the exact pattern of cell loss and to map the cellular distribution of candidate pathogenic molecules, it is necessary to have landmarks independent of the degenerative process by which to subdivide the substantia nigra. We have developed a protocol for this purpose based on immunostaining for calbindin D<sub>28K</sub>, a protein present in striatonigral afferent fibres. We used it to examine post-mortem brain samples from seven subjects who had had no history of neurological or psychiatric disease. We found intense immunostaining for calbindin D<sub>28K</sub> associated with the neuropil of the ventral midbrain. Within the calbindin-positive region, there were conspicuous calbindin-poor zones. Analysed in serial sections, many of the calbindin-poor zones seen in individual sections were continuous with one another, forming elements of larger, branched three-dimensional structures. Sixty per cent of all dopamine-containing neurons in the substantia nigra pars compacta were located within the calbindin-rich zone, which we named the nigral matrix, and 40% were packed together within the calbindin-poor zones, which we named nigrosomes. We identified five different nigrosomes. This organization was consistent from one control brain to another. We propose that subdivision of the human substantia nigra based on patterns of calbindin immunostaining provides a key tool for analysing the organization of the substantia nigra and offers a new approach to analysing molecular expression patterns in the substantia nigra and the specific patterns of nigral cell degeneration in Parkinson's disease.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0006-8950</s0></fA01><fA03 i2="1"><s0>Brain</s0></fA03><fA05><s2>122</s2></fA05><fA06><s3>p.8</s3></fA06><fA08 i1="01" i2="1" l="ENG"><s1>The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D<sub>28K</sub> immunohistochemistry</s1></fA08><fA11 i1="01" i2="1"><s1>DAMIER (P.)</s1></fA11><fA11 i1="02" i2="1"><s1>HIRSCH (E. C.)</s1></fA11><fA11 i1="03" i2="1"><s1>AGID (Y.)</s1></fA11><fA11 i1="04" i2="1"><s1>GRAYBIEL (A. M.)</s1></fA11><fA14 i1="01"><s1>INSERM U289, Hôpital de la Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></fA14><fA14 i1="02"><s1>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology</s1><s2>Cambridge, Massachusetts</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></fA14><fA20><s1>1421-1436</s1></fA20><fA21><s1>1999</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>998</s2><s5>354000089290940030</s5></fA43><fA44><s0>0000</s0><s1>© 1999 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>28 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>99-0413078</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Brain</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>Parkinson's disease is characterized by massive degeneration of dopamine-containing neurons in the midbrain. However, the vulnerability of these neurons is heterogeneous both across different midbrain dopamine-containing cell groups and within the substantia nigra, the brain structure most affected in this disease. To determine the exact pattern of cell loss and to map the cellular distribution of candidate pathogenic molecules, it is necessary to have landmarks independent of the degenerative process by which to subdivide the substantia nigra. We have developed a protocol for this purpose based on immunostaining for calbindin D<sub>28K</sub>, a protein present in striatonigral afferent fibres. We used it to examine post-mortem brain samples from seven subjects who had had no history of neurological or psychiatric disease. We found intense immunostaining for calbindin D<sub>28K</sub> associated with the neuropil of the ventral midbrain. Within the calbindin-positive region, there were conspicuous calbindin-poor zones. Analysed in serial sections, many of the calbindin-poor zones seen in individual sections were continuous with one another, forming elements of larger, branched three-dimensional structures. Sixty per cent of all dopamine-containing neurons in the substantia nigra pars compacta were located within the calbindin-rich zone, which we named the nigral matrix, and 40% were packed together within the calbindin-poor zones, which we named nigrosomes. We identified five different nigrosomes. This organization was consistent from one control brain to another. We propose that subdivision of the human substantia nigra based on patterns of calbindin immunostaining provides a key tool for analysing the organization of the substantia nigra and offers a new approach to analysing molecular expression patterns in the substantia nigra and the specific patterns of nigral cell degeneration in Parkinson's disease.</s0></fC01><fC02 i1="01" i2="X"><s0>002B24O09</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Locus niger</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Locus niger</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Locus níger</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Immunohistochimie</s0><s5>04</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Immunohistochemistry</s0><s5>04</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Inmunohistoquímica</s0><s5>04</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Cholécalcine</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Calbindin</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Coleocalcina</s0><s5>07</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Neurone dopaminergique</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Dopaminergic neuron</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Neurona dopaminérgica</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Dopamine</s0><s2>NK</s2><s2>FR</s2><s5>11</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Dopamine</s0><s2>NK</s2><s2>FR</s2><s5>11</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Dopamina</s0><s2>NK</s2><s2>FR</s2><s5>11</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Cartographie</s0><s5>13</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Cartography</s0><s5>13</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Cartografía</s0><s5>13</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Reproductibilité</s0><s5>16</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Reproducibility</s0><s5>16</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Reproductividad</s0><s5>16</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Exploration</s0><s5>17</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Exploration</s0><s5>17</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Exploración</s0><s5>17</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Méthode</s0><s5>18</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Method</s0><s5>18</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Método</s0><s5>18</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Validité</s0><s5>19</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Validity</s0><s5>19</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Validez</s0><s5>19</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Homme</s0><s5>20</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Human</s0><s5>20</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Hombre</s0><s5>20</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Encéphale</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Brain (vertebrata)</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso central</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Anatomopathologie</s0><s5>45</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Pathology</s0><s5>45</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Anatomía patológica</s0><s5>45</s5></fC07><fN21><s1>263</s1></fN21></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B66 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001B66 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:99-0413078
|texte= The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D28K immunohistochemistry
}}
| This area was generated with Dilib version V0.6.29. |  |